Abstract
Diffuse intrinsic pontine gliomas (DIPG) is an incurable neoplasm occurring mainly in children for which no progress was made in the last decades. The randomized phase II BIOMEDE trial compared three drugs (everolimus, dasatinib, erlotinib) combined with irradiation. The present report describes whole exome sequencing (WES) results for the first 100 patients randomized.
Copy-number-Alteration (CNA) unsupervised clustering identified four groups with different outcomes and biology. This classification improved prognostication compared to models based on known biomarkers (Histone H3 and TP53 mutations). The cluster presenting complex genomic rearrangements was associated with significantly worse outcome and TP53 dysfunction. Mutation and CNA signatures confirmed the frequent alteration in DNA repair machinery. With respect to potential targetable pathways, PI3K/AKT/mTOR activation occurred in all the samples through multiples mechanisms. In conclusion, WES at diagnosis was feasible in most patients and provides a better patient stratification and theranostic information for precision medicine.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT02233049
Funding Statement
We acknowledge also the support of the Institut National du Cancer (Programme Hospitalier de Recherche Clinique), the charities Imagine for Margo (to TK and JG), l'Etoile de Martin (to DC) and the Lemos Family (to JG).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB 'Comite de Protection des Personnes d'Ile de France' provided an approval on July 22nd 2014 for the research within the BIOMEDE clinical trial under the file # 2014-001929-32. The French oversight body 'Agence Nationale de Securite du medicament et des produits de sante' (ANSM) delivered an autorization for the clinical trial and associated biomedical research under the reference 140670A-12 on August 6th 2014.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are currently being deposited on EGA (https://ega-archive.org). Please contact authors for updates.